Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK

References

• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• World Health Organization. Diabetes - country and regional data. 2010. Available at: http://www.who.int/diabetes/facts/world_figures/en/
   Google Scholar
• Gonzalez EL, Johansson S, Wallander MA, et al. Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J Epidemiol Community Health 2009;63:332-6
   PubMed Web of Science ®Google Scholar
• Brunner EJ, Mosdol A, Witte DR, et al. Dietary patterns and 15-year risks of major coronary events, diabetes, and mortality. Am J Clin Nutr 2008;87:1414-21
   PubMed Web of Science ®Google Scholar
• Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359:2220-32
   PubMed Web of Science ®Google Scholar
• Perry IJ, Wannamethee SG, Walker MK, et al. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 1995;310:560-4
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas. Economic impact of diabetes. 2010 [Accessed 2010 Mar 23]. Available at: http://www.diabetesatlas.org/content/economic-impacts-diabetes
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
   Google Scholar
• UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-9
   PubMed Web of Science ®Google Scholar
• Gulliford MC, Dodhia H, Sivaprasad S, et al. Family practices' achievement of diabetes quality of care targets and risk of screen-detected diabetic retinopathy. PLoS One 2010;5:e10424
   Web of Science ®Google Scholar
• Leese GP, Boyle P, Feng Z, et al. Screening uptake in a well-established diabetic retinopathy screening program: the role of geographical access and deprivation. Diabetes Care 2008;31:2131-5
   PubMed Web of Science ®Google Scholar
• Exenatide (Byetta) Summary of Product Characteristics. 2010 May 4 [Accessed 2010 July 20]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf
   Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in significantly greater improvement in glycemic control with less nausea than exenatide twice daily in patients with type 2 diabetes. American Diabetes Association Annual Meeting 2010 Abstract 0008-LB. 2010
   Google Scholar
• Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. type 2 diabetes: newer agents. May 2009
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-40
   PubMed Web of Science ®Google Scholar
• Eli Lilly and company. GWBR Clinical Study Report, 2009
   Google Scholar
• National Institute for Clinical Excellence. NICE short clinical guideline 87 – type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. May 2009. Available at http://www.nice.org.uk/cg87
   Google Scholar
• UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249-58
   PubMed Web of Science ®Google Scholar
• Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1 Pt 2):136-45
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
   PubMed Web of Science ®Google Scholar
• DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy. New York: McGraw-Hill, 2008
   Google Scholar
• Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
   PubMed Web of Science ®Google Scholar
• Haymarket Medical Media. Monthly Index of Medical Specialties, August 2009. Available at: www.mims.co.uk
   Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence 2008. Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
   Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2010; Mar 12 [Epub ahead of print]
   Google Scholar
• Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005
   Google Scholar
• Appleby J, Devlin N, Parkin D. NICE’s cost effectiveness threshold. BMJ 2007;335:358-9
   PubMed Web of Science ®Google Scholar
• Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-22
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Liraglutide for the treatment of type 2 diabetes mellitus. Appraisal consultation document. 2010 June 14 [Accessed 2010 July 21]. Available at: http://www.nice.org.uk/guidance/index.jsp?action=article&o=49173
   Google Scholar
• Liraglutide (Victoza) Summary of Product Characteristics. 2010 February 22 [Accessed 2010 Jul 21]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf
   Google Scholar
• Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther 2006;28:1989-95
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004;19:1594-9
   PubMed Web of Science ®Google Scholar
• Sharma S, Oliver-Fernandez A, Bakal J, et al. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Ophthalmol 2003;87:259-61
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618-24
   PubMed Web of Science ®Google Scholar
• Hopkins RB, Tarride JE, Bowen J, et al. Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Can J Ophthalmol 2008;43:213-17
   PubMed Web of Science ®Google Scholar
• Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004;30:549-56
   PubMed Web of Science ®Google Scholar
• Davies R, Wittrup-Jensen KU, Peters JR, et al. The impact on health-related quality of life (EQ-5Dindex) in people with type 1 diabetes who experience severe hypoglycemia. Diabetologia 2005;48(Suppl 1):A292
   Google Scholar
• National Institute for Clinical Excellence. Technology appraisal guidance -- No. 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes -- insulin glargine. December, 2002
   Google Scholar
• National Health Service. Prescription Cost Analysis 2008. 2009 April 21. Available at: http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-2008
   Google Scholar
• Melville A, Richardson R, McIntosh A, et al. Complications of diabetes: screening for retinopathy and management of foot ulcers. Qual Health Care 2000;9:137-41
   PubMedGoogle Scholar
• Personal Social Services Research Unit UK. Unit Costs of Health and Social Care 2008. Canterbury, UK: University of Kent
   Google Scholar
• National Health Service. NHS reference costs 2007-08. 2009 August 5. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098945
   Google Scholar
• Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442-50
   PubMed Web of Science ®Google Scholar
• The National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians, 2008
   Google Scholar
• Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care 2002;11:70-4
   PubMedGoogle Scholar